5 results about "Chronic stage" patented technology

The invention relates to the technical field of markers, in particular to application of a biomarker for identifying acute stage and chronic stage of brucellosis. A series of biomarkers related to acute and chronic stages of brucellosis are screened and found, and the biomarkers have obvious difference between acute and chronic brucellosis patients. The biomarkers can realize acute and chronic staging of brucellosis, are high in sensitivity and specificity, and have relatively good diagnosis efficiency. A novel molecular diagnosis tool is provided for acute and chronic staging of brucellosis, the problems that existing serological detection is low in specificity, and clinical staging cannot be accurately judged are solved, and wide application prospects are achieved.

A method and system for differentiating acute and chronic pain based on the functional state of specific neural circuits is proposed. This method utilizes in vivo two-photon / endoscopic calcium imaging and ex vivo brain slice patch-clamp techniques to longitudinally monitor the activity dynamics of neurons in the DRN and ZI brain regions during the acute and chronic phases of a neuropathic pain model. By extracting and analyzing calcium and electrophysiological signal parameter sets, distinguishing criteria are established: if the activity of 5-HTergic neurons in the DRN is specifically enhanced in the acute phase, the indication is acute pain; if the activity of GABAergic neurons in the ZI is specifically enhanced in the chronic phase, the indication is chronic pain. This invention achieves an objective and precise differentiation of the transition from acute to chronic pain at the level of specific neural circuits, providing a new strategy and tool for pain mechanism research and clinical diagnosis and treatment.

The invention discloses an application of sanguisorba officinalis sapogenin in preparation of a medicine for treating gout. Compared with the prior art, it is found for the first time that sanguisorba sapogenin can treat gout, especially acute gouty arthritis. Animal research proves that the sanguisorba sapogenin can remarkably relieve joint swelling and tissue damage caused by acute gouty arthritis by inhibiting release of inflammatory factors such as IL-1beta and TNF-alpha. Meanwhile, the sanguisorba sapogenin can also remarkably reduce the level of serum uric acid, and also has a certain treatment effect on gout in a remission stage and a chronic stage. Therefore, the sanguisorba officinalis sapogenin can be used for treating gout and has the potential and prospect of being prepared into the anti-gout medicine.

The application relates to the technical field of markers, in particular to application of biomarkers for identifying acute and chronic stages of brucellosis. A series of biomarkers related to acute and chronic stages of brucellosis are screened and found, and the biomarkers are significantly different between patients with acute and chronic brucellosis. The biomarkers can be used to realize acute and chronic staging of brucellosis, and have high sensitivity and specificity and good diagnostic efficiency. The application provides a new molecular diagnostic tool for acute and chronic staging of brucellosis, solves the problems of low specificity of existing serological detection and incapability of accurately judging clinical stages, and has a wide application prospect.

The invention relates to an allicin-containing pharmaceutical composition for treating eczema and a preparation method of the allicin-containing pharmaceutical composition, and belongs to the technical field of pharmaceutical compositions. In order to solve the problem that an existing eczema treatment medicine is difficult to consider anti-inflammatory, antibacterial and skin barrier repair at the same time, the invention provides the allicin-containing pharmaceutical composition for treating eczema, and the allicin-containing pharmaceutical composition contains the following effective pharmaceutical ingredients: an allicin inclusion compound, ceramide, sophocarpidine, baicalin, forsythin, asiaticoside and glycyrrhizic acid. Through scientific compatibility of various active components, an antibacterial-anti-inflammatory-repair triple synergistic treatment system is constructed, and the treatment targets of rapid symptom control in the acute stage, continuous repair in the chronic stage and prevention of infection and recurrence in the whole process of eczema treatment are achieved. Aiming at the defect of strong irritation of the allicin, the pharmaceutical composition containing the allicin is prepared into an oil-in-water cream form, so that the problems of stability and irritation of active ingredients of the allicin are solved, and the treatment targets of high efficiency and low toxicity are realized.